COVID Vaccines Development/Procurement/Distribution/Policy – Russia, China

Milestones :: Perspectives :: Research

 

COVID Vaccines Development/Procurement/Distribution/Policy – Russia, China

Russia: Sputnik V – “the first registered COVID-19 vaccine” [to 23 Jan 2021]
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Hungary becomes the first country in EU to authorize the Sputnik V vaccine
Press release, 21.01.2021 12:20:00
…The vaccine was approved under the emergency use authorization procedure. The approval is based on the results of the clinical trials of Sputnik V in Russia and a comprehensive assessment of the vaccine by experts in Hungary…

Ministry of Health of the UAE has approved the use of Sputnik V vaccine
Press release, 21.01.2021
…The vaccine was registered under the emergency use authorization procedure based on the results of the Russian Phase III clinical trials which included over 33,000 subjects. Moreover, local Phase III clinical trials of Sputnik V in the UAE are ongoing under the supervision of the MOHAP and Department of Health (DOH) of Abu Dhabi with 1,000 volunteers already enrolled into the study. Medical protocols are handled by the public health provider, the Abu Dhabi Health Services Company, SEHA…

Turkmenistan has become the first country in Central Asia to register Sputnik V vaccine
Press release, 18.01.2021
…The vaccine was approved under the emergency use authorization procedure without additional clinical trials in Turkmenistan…

RDIF and the Gamaleya Center announce creation of International scientific advisory board on Sputnik V vaccine represented by leading scientists from 9 countries
Moscow, January 18, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya (Gamaleya Center) announce the creation of an International Scientific Advisory Board on the Sputnik V vaccine – the world’s first registered vaccine against coronavirus.
Leading scientists in virology, microbiology, genetics and biotechnology from Argentina, Croatia, France, Germany, India, Russia, Sweden, UK and USA, representing top research and medical centers, have joined the Board.
The list of participants of the International scientific advisory board on Sputnik V vaccine:
1. Carlos Zala, Adjunct Professor, Department of Microbiology, University of Buenos Aires, School of Medicine, Argentina;
2. Omar Sued, President of the society of infectologists, Argentina;
3. Dragomira Majhen, Dr.Sc., Senior research associate, Scientist, Laboratory for Cell Biology and Signalling Division of Molecular Biology Ruđer Bošković Instiute, Croatia;
4. Cecil Czerkinsky, PhD, M.D., Research Director, Institute of Molecular and Cellular Pharmacology, France
5. Wibke Bayer, Privatdozentin, Principal Investigator on Vaccine Development, the Institute for Virology of the University Hospital in Essen, University Duisburg-Essen, Germany;
6. Vasanthapuram Ravi, MBBS, M.D. Microbiology, Dean, Basic Sciences, National Institute of Mental Health and Neurosciences (NIMHANS), India;
7. Niklas Arnberg, Professor of Virology, Umeå University, Sweden;
8. David Livermore, Professor of Medical Microbiology at the University of East Anglia, UK;
9. Len Seymour, Professor of Gene Therapies in the Department of Oncology at the University of Oxford, UK;
10. Hildegund C.J. Ertl, M.D., Professor, Vaccine & Immunotherapy Center, The Wistar Institute, USA;
11. Ronald Rodriguez, M.D., Ph.D., Professor of Urology, University of Texas Health Science Center at San Antonio, USA;
12. David A. Ornelles, Ph.D., Associate Professor of Microbiology & Immunology, Wake Forest School of Medicine Biotech Place, USA;
13. Alexander Gintsburg, RAS Academician, Professor, Director of the Gamaleya Center;
14. Denis Logunov, RAS Corresponding Member, Doctor of Biological Sciences, Deputy Director for Science of the Gamaleya Center;
15. Sergey Tsarenko, Professor, Faculty of Medicine, Lomonosov Moscow State University, Deputy Chief Physician for Anesthesiology and Reanimation at Hospital No. 52 in Moscow;
16. Alexander Rumyantsev, President of Dmitry Rogachev National Research Center, RAS Academician, M.D., Professor.

 

::::::

China: COVID-19 Vaccines – Announcement/Regulatory Actions/Deployment

National Health Commission of the People’s Republic of China [to 23 Jan 2021]
http://en.nhc.gov.cn/
China calls for international vaccine cooperation to defeat COVID-19 pandemic
2021-01-21
BEIJING — China calls on the international community to work together to contribute to the equitable distribution and use of COVID-19 vaccines around the world and help defeat the pandemic, a foreign ministry spokesperson said on Jan 20.

Spokesperson Hua Chunying made the remarks in response to a question about China’s expectations of promoting international cooperation on COVID-19 vaccines.

“We have always maintained that the virus knows no borders and humanity shares a common destiny. Solidarity and cooperation are the most powerful weapon to defeat the COVID-19 pandemic. It is also the common consensus of the international community,” Hua said at a press briefing.

China is at the forefront of vaccine research and development globally, with one vaccine for conditional marketing and several others being in clinical trials at different stages, Hua said, adding that this has provided significant support for China’s fight against the pandemic and its participation in international cooperation on vaccines.

Currently, China has started the vaccination of key groups, and the domestic demand for vaccines is huge, Hua said, adding that while meeting domestic demand, China has overcome difficulties and made every effort to carry out international cooperation on vaccines with other countries, especially developing countries, in different ways, and provided support and assistance within China’s capabilities according to their needs.

Chinese enterprises are conducting joint vaccine research and development with partners in more than 10 countries, including clinical trials and production. As part of the cooperation, Chinese enterprises have provided vaccines to partner countries, Hua said.

Chinese companies have started to export to countries that urgently need vaccines, have approved Chinese vaccines, and have authorized the emergency use of Chinese vaccines in their countries. “Most of them are developing countries,” she added.

China has joined the WHO-led COVAX initiative to support the G20 in promoting international cooperation on vaccines and multilateral cooperation to promote the equitable global distribution of vaccines, the spokesperson said…